Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients

Stefano De Servi; Nuccia Morici; Enrico Boschetti; Roberta Rossini; Paola Martina; Giuseppe Musumeci; Maurizio D'Urbano; Ludovico Lazzari; Carlo La Vecchia; Michele Senni; Silvio Klugmann; Stefano Savonitto

doi:10.1016/j.vph.2015.11.085

Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients

Stefano De Servi, Nuccia Morici, Enrico Boschetti, Roberta Rossini, Paola Martina, Giuseppe Musumeci, Maurizio D'Urbano, Ludovico Lazzari, Carlo La Vecchia, Michele Senni, Silvio Klugmann, Stefano Savonitto

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article

Abstract

Intravenous administration of a short acting glycoprotein IIb/IIIa inhibitor has been proposed as a bridge to surgery in patients on dual antiplatelet treatment, but data in comparison with other treatment options are not available. We conducted a retrospective analysis of consecutive patients who underwent un-deferrable, non-emergency surgery after coronary stenting. The bridge therapy was performed after discontinuation of the oral P2Y₁₂ inhibitor by using i.v. tirofiban infusion. Net Adverse Clinical Events (NACE) was the primary outcome.We analyzed 314 consecutive patients: the bridge strategy was performed in 87 patients, whereas 227 were treated with other treatment options and represent the control group. Thirty-day NACE occurred in 8% of patients in the bridge group and in 22.5% in the control group (p.

Original language	English
Journal	Vascular Pharmacology
DOIs	https://doi.org/10.1016/j.vph.2015.11.085
Publication status	Accepted/In press - Aug 31 2015

Keywords

ADP receptors
Coronary syndrome
Platelet glycoproteins

ASJC Scopus subject areas

Pharmacology
Molecular Medicine
Physiology

Access to Document

10.1016/j.vph.2015.11.085

Fingerprint Dive into the research topics of 'Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients'. Together they form a unique fingerprint.

Cite this

Bridge therapy or standard treatment for urgent surgery after coronary stent implantation : Analysis of 314 patients. / De Servi, Stefano; Morici, Nuccia; Boschetti, Enrico; Rossini, Roberta; Martina, Paola; Musumeci, Giuseppe; D'Urbano, Maurizio; Lazzari, Ludovico; La Vecchia, Carlo; Senni, Michele; Klugmann, Silvio; Savonitto, Stefano.

In: Vascular Pharmacology, 31.08.2015.

Research output: Contribution to journal › Article

De Servi, Stefano ; Morici, Nuccia ; Boschetti, Enrico ; Rossini, Roberta ; Martina, Paola ; Musumeci, Giuseppe ; D'Urbano, Maurizio ; Lazzari, Ludovico ; La Vecchia, Carlo ; Senni, Michele ; Klugmann, Silvio ; Savonitto, Stefano. / Bridge therapy or standard treatment for urgent surgery after coronary stent implantation : Analysis of 314 patients. In: Vascular Pharmacology. 2015.

@article{763f3584ee1840288eeac948cb9e4600,

title = "Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients",

abstract = "Intravenous administration of a short acting glycoprotein IIb/IIIa inhibitor has been proposed as a bridge to surgery in patients on dual antiplatelet treatment, but data in comparison with other treatment options are not available. We conducted a retrospective analysis of consecutive patients who underwent un-deferrable, non-emergency surgery after coronary stenting. The bridge therapy was performed after discontinuation of the oral P2Y12 inhibitor by using i.v. tirofiban infusion. Net Adverse Clinical Events (NACE) was the primary outcome.We analyzed 314 consecutive patients: the bridge strategy was performed in 87 patients, whereas 227 were treated with other treatment options and represent the control group. Thirty-day NACE occurred in 8% of patients in the bridge group and in 22.5% in the control group (p. ",

keywords = "ADP receptors, Coronary syndrome, Platelet glycoproteins",

author = "{De Servi}, Stefano and Nuccia Morici and Enrico Boschetti and Roberta Rossini and Paola Martina and Giuseppe Musumeci and Maurizio D'Urbano and Ludovico Lazzari and {La Vecchia}, Carlo and Michele Senni and Silvio Klugmann and Stefano Savonitto",

year = "2015",

month = aug,

day = "31",

doi = "10.1016/j.vph.2015.11.085",

language = "English",

journal = "Vascular Pharmacology",

issn = "1537-1891",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Bridge therapy or standard treatment for urgent surgery after coronary stent implantation

T2 - Analysis of 314 patients

AU - De Servi, Stefano

AU - Morici, Nuccia

AU - Boschetti, Enrico

AU - Rossini, Roberta

AU - Martina, Paola

AU - Musumeci, Giuseppe

AU - D'Urbano, Maurizio

AU - Lazzari, Ludovico

AU - La Vecchia, Carlo

AU - Senni, Michele

AU - Klugmann, Silvio

AU - Savonitto, Stefano

PY - 2015/8/31

Y1 - 2015/8/31

N2 - Intravenous administration of a short acting glycoprotein IIb/IIIa inhibitor has been proposed as a bridge to surgery in patients on dual antiplatelet treatment, but data in comparison with other treatment options are not available. We conducted a retrospective analysis of consecutive patients who underwent un-deferrable, non-emergency surgery after coronary stenting. The bridge therapy was performed after discontinuation of the oral P2Y12 inhibitor by using i.v. tirofiban infusion. Net Adverse Clinical Events (NACE) was the primary outcome.We analyzed 314 consecutive patients: the bridge strategy was performed in 87 patients, whereas 227 were treated with other treatment options and represent the control group. Thirty-day NACE occurred in 8% of patients in the bridge group and in 22.5% in the control group (p.

AB - Intravenous administration of a short acting glycoprotein IIb/IIIa inhibitor has been proposed as a bridge to surgery in patients on dual antiplatelet treatment, but data in comparison with other treatment options are not available. We conducted a retrospective analysis of consecutive patients who underwent un-deferrable, non-emergency surgery after coronary stenting. The bridge therapy was performed after discontinuation of the oral P2Y12 inhibitor by using i.v. tirofiban infusion. Net Adverse Clinical Events (NACE) was the primary outcome.We analyzed 314 consecutive patients: the bridge strategy was performed in 87 patients, whereas 227 were treated with other treatment options and represent the control group. Thirty-day NACE occurred in 8% of patients in the bridge group and in 22.5% in the control group (p.

KW - ADP receptors

KW - Coronary syndrome

KW - Platelet glycoproteins

UR - http://www.scopus.com/inward/record.url?scp=84949643826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949643826&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2015.11.085

DO - 10.1016/j.vph.2015.11.085

M3 - Article

AN - SCOPUS:84949643826

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

ER -